Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases. The company has a market capitalization of $83.7 billion and has become one of the largest biotech firms in the world through its expertise in antibody technologies, genetics-driven drug discovery, and innovative biologic therapies.
The biotech titan's shares have underperformed the broader market over the past year and in 2026. REGN stock has surged 7% over the past 52 weeks and is down 17.2% on a YTD basis. In comparison, the S&P 500 Index ($SPX) has returned 27.9% over the past year and 9.2% in 2026.